Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337747 | 0.98 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL338389 | 0.98 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL1010667 | 0.98 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL338380 | 0.98 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL337303 | 0.98 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL29069493 | 0.98 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5859388 | 0.93 | CA2 (0.56) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL8667648 | 0.90 | GPR84 (0.47) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5708609 | 0.90 | GPR84 (0.47) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL24106546 | 0.89 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217574-B1 | METHOD FOR PRODUCING IONIC LIQUIDS BY ANION EXCHANGE | BASF SE (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-8389740-B2 | Process for preparing ionic liquids by anion exchange | BASF SE (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20100217010-A1 | PROCESS FOR PREPARING IONIC LIQUIDS BY ANION EXCHANGE | BASF SE (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-2217574-A1 | METHOD FOR PRODUCING IONIC LIQUIDS BY ANION EXCHANGE | BASF SE (DE) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009059934-A1 | METHOD FOR PRODUCING IONIC LIQUIDS BY ANION EXCHANGE | BASF SE (DE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2006027069-A1 | METHOD FOR PRODUCING HETEROCYCLIC QUATERNARY AMMONIUM AND/OR GUANIDINIUM COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027070-A1 | METHOD FOR THE PRODUCTION OF HETEROCYCLIC QUATERNARY AMMONIUM COMPOUNDS AND/OR GUANIDINE COMPOUNDS HAVING HIGH PURITY | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-16 | — | — | WO | disclosed |
| US-5800731-A | Homogeneous electroviscous fluids using aluminum compounds | RWE-DEA AKTIENGESELLSCHAFT FUR MINERALOEL UND CHEMIE (DE) | 1998-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217010-A1 | PROCESS FOR PREPARING IONIC LIQUIDS BY ANION EXCHANGE | NXF1, SLC1A5, NPM1 | GPR84 4681/4885FFAR1 2115/4885MAPT 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.